BR0107333A - Formulação farmacêutica, uso da mesma, métodos para tratamento profilático ou terapêutico de um indivìduo sofrendo de, ou susceptìvel a, hipercolesterolemia e diarréia, e, uso de um aglutinante de ácidos biliares - Google Patents
Formulação farmacêutica, uso da mesma, métodos para tratamento profilático ou terapêutico de um indivìduo sofrendo de, ou susceptìvel a, hipercolesterolemia e diarréia, e, uso de um aglutinante de ácidos biliaresInfo
- Publication number
- BR0107333A BR0107333A BR0107333-8A BR0107333A BR0107333A BR 0107333 A BR0107333 A BR 0107333A BR 0107333 A BR0107333 A BR 0107333A BR 0107333 A BR0107333 A BR 0107333A
- Authority
- BR
- Brazil
- Prior art keywords
- bile acid
- diarrhea
- acid binder
- pharmaceutical formulation
- prophylactic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
"FORMULAçãO FARMACêUTICA, USO DA MESMA, MéTODOS PARA TRATAMENTO PROFILáTICO OU TERAPêUTICO DE UM INDIVìDUO SOFRENDO DE, OU SUSCEPTìVEL A, HIPERCOLESTEROLEMIA E DIARRéIA, E, USO DE UM AGLUTINANTE DE áCIDOS BILIARES". Uma formulação farmacêutica oral, compreendendo um composto inibidor do transporte do ácido biliar ileal (inibidor de IBAT), um inibidor da redutase Co-A HMG e um veículo terapeuticamente aceitável, caracterizada pelo fato da formulação ser projetada para suprir o inibidor de IBAT no íleo e o inibidor da redutase Co A HBG não especificamente dentro do trato GI. O composto inibidor de IBAT e o inibidor da redutase Co-A HMG podem também ser administrados em combinação com um aglutinante do ácido biliar, para aliviar possíveis efeitos colaterais da terapia com compostos inibidores de IBAT, tais como, por exemplo, diarréia. O aglutinante do ácido biliar pode ser formulado para liberação no cólon.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0003766A SE0003766D0 (sv) | 2000-10-18 | 2000-10-18 | Novel formulation |
PCT/GB2001/004525 WO2002032428A1 (en) | 2000-10-18 | 2001-10-12 | Oral formulation comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0107333A true BR0107333A (pt) | 2002-08-27 |
Family
ID=20281462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0107333-8A BR0107333A (pt) | 2000-10-18 | 2001-10-12 | Formulação farmacêutica, uso da mesma, métodos para tratamento profilático ou terapêutico de um indivìduo sofrendo de, ou susceptìvel a, hipercolesterolemia e diarréia, e, uso de um aglutinante de ácidos biliares |
Country Status (19)
Country | Link |
---|---|
US (1) | US20050101611A1 (pt) |
EP (1) | EP1351692A1 (pt) |
JP (1) | JP2004511521A (pt) |
KR (1) | KR20020062970A (pt) |
CN (1) | CN1400902A (pt) |
AU (1) | AU2001294002A1 (pt) |
BR (1) | BR0107333A (pt) |
CA (1) | CA2425831A1 (pt) |
HU (1) | HUP0301087A3 (pt) |
IL (1) | IL150104A0 (pt) |
IS (1) | IS6784A (pt) |
MX (1) | MXPA03003417A (pt) |
NO (1) | NO20022894L (pt) |
NZ (1) | NZ525371A (pt) |
PL (1) | PL360937A1 (pt) |
SE (1) | SE0003766D0 (pt) |
SK (1) | SK4732003A3 (pt) |
WO (1) | WO2002032428A1 (pt) |
ZA (1) | ZA200204771B (pt) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0000772D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
AU2002329387B2 (en) | 2001-09-08 | 2007-06-07 | Albireo Ab | Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (IBAT) inhibitory activity for the treatment hyperlipidaemia |
SE0104333D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
DE60319084T2 (de) | 2002-06-20 | 2009-01-29 | Astrazeneca Ab | Ortho-substituierte benzoesäurederivate zur behandlung von insulinresistenz |
GB0216321D0 (en) * | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Therapeutic treatment |
GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
PL2637646T3 (pl) * | 2010-11-08 | 2017-01-31 | Albireo Ab | Kombinacja farmaceutyczna zawierająca inhibitor ibat i środek wiążący kwasy żółciowe |
AU2011326871B2 (en) | 2010-11-08 | 2015-02-12 | Albireo Ab | IBAT inhibitors for the treatment of liver diseases |
PL2771003T3 (pl) | 2011-10-28 | 2017-10-31 | Lumena Pharmaceuticals Llc | Inhibitory ponownego wykorzystania kwasów żółciowych do leczenia pediatrycznych cholestatycznych chorób wątroby |
JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
WO2015199147A1 (ja) | 2014-06-25 | 2015-12-30 | 味の素株式会社 | 固形製剤及びその着色防止又は着色低減方法 |
EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
CN105362244A (zh) * | 2015-11-26 | 2016-03-02 | 青岛海之源智能技术有限公司 | 考来烯胺缓释片及制备方法 |
US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
ES2874546T3 (es) | 2016-02-09 | 2021-11-05 | Albireo Ab | Formulación oral de colestiramina y uso de la misma |
WO2017138877A1 (en) | 2016-02-09 | 2017-08-17 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
CA3071182A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | Cholestyramine pellets, oral cholestyramine formulations and use thereof |
CN111032019B (zh) | 2017-08-09 | 2022-07-05 | 阿尔比里奥公司 | 考来烯胺颗粒、口服考来烯胺制剂及其用途 |
CN112449637B (zh) | 2018-06-05 | 2024-03-19 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
MX2020013774A (es) | 2018-06-20 | 2021-03-02 | Albireo Ab | Modificaciones de cristales de odevixibat. |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
CA3127408A1 (en) | 2019-02-06 | 2020-08-13 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
PT3921028T (pt) | 2019-02-06 | 2023-02-15 | Albireo Ab | Compostos de benzotiadiazepina e a sua utilização como moduladores de ácido biliar |
AR120674A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzotiazepina y su uso como ácido biliar |
US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
EP4069361B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
AR120676A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como ácido biliar |
EP4069247A1 (en) | 2019-12-04 | 2022-10-12 | Albireo AB | Benzothiadiazepine compounds and their use as bile acid modulators |
AR120679A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar |
BR112022010505A2 (pt) | 2019-12-04 | 2022-09-06 | Albireo Ab | Compostos de benzotia(di)azepina e seu uso como moduladores do ácido biliar |
AR120682A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar |
CA3158276A1 (en) | 2019-12-04 | 2021-06-10 | Per-Goran Gillberg | Benzothia(di)azepine compounds and their use as bile acid modulators |
TW202134222A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途 |
CN116157389A (zh) | 2020-08-03 | 2023-05-23 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
CA3196488A1 (en) | 2020-11-12 | 2022-05-19 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
AU2021390172A1 (en) | 2020-12-04 | 2023-06-22 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
US20230398125A1 (en) | 2022-06-09 | 2023-12-14 | Albireo Ab | Treating hepatitis |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4600578A (en) * | 1984-05-11 | 1986-07-15 | Bristol-Myers Company | Method of inhibiting diarrhea |
US5362732A (en) * | 1989-12-20 | 1994-11-08 | University Of North Carolina At Chapel Hill | Boronated compounds |
JPH04193836A (ja) * | 1990-11-26 | 1992-07-13 | Banyu Pharmaceut Co Ltd | 抗高脂血症剤 |
FI108451B (fi) * | 1991-12-20 | 2002-01-31 | Hoechst Ag | Menetelmõ polymeeristen ja oligomeeristen sappihappojohdannaisten valmistamiseksi |
IL108633A (en) * | 1993-02-15 | 1998-07-15 | Wellcome Found | History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them |
JPH07223970A (ja) * | 1994-02-10 | 1995-08-22 | Tanabe Seiyaku Co Ltd | 消化管内適所放出製剤 |
GB9704208D0 (en) * | 1997-02-28 | 1997-04-16 | Glaxo Group Ltd | Chemical compounds |
RU2247579C2 (ru) * | 1997-03-11 | 2005-03-10 | Джи. Ди. Сирл Энд Ко. | Комбинированное лечение с применением бензотиепинов, ингибирующих транспорт желчной кислоты в подвздошной кишке, и ингибиторов hmg co-а редуктазы |
GB9800428D0 (en) * | 1998-01-10 | 1998-03-04 | Glaxo Group Ltd | Chemical compounds |
-
2000
- 2000-10-18 SE SE0003766A patent/SE0003766D0/xx unknown
-
2001
- 2001-10-12 KR KR1020027007742A patent/KR20020062970A/ko not_active Application Discontinuation
- 2001-10-12 EP EP01974487A patent/EP1351692A1/en not_active Withdrawn
- 2001-10-12 US US10/399,336 patent/US20050101611A1/en not_active Abandoned
- 2001-10-12 IL IL15010401A patent/IL150104A0/xx unknown
- 2001-10-12 JP JP2002535666A patent/JP2004511521A/ja not_active Withdrawn
- 2001-10-12 AU AU2001294002A patent/AU2001294002A1/en not_active Abandoned
- 2001-10-12 CN CN01804901A patent/CN1400902A/zh active Pending
- 2001-10-12 BR BR0107333-8A patent/BR0107333A/pt not_active IP Right Cessation
- 2001-10-12 WO PCT/GB2001/004525 patent/WO2002032428A1/en not_active Application Discontinuation
- 2001-10-12 HU HU0301087A patent/HUP0301087A3/hu unknown
- 2001-10-12 CA CA002425831A patent/CA2425831A1/en not_active Abandoned
- 2001-10-12 NZ NZ525371A patent/NZ525371A/en unknown
- 2001-10-12 MX MXPA03003417A patent/MXPA03003417A/es unknown
- 2001-10-12 SK SK473-2003A patent/SK4732003A3/sk unknown
- 2001-10-12 PL PL36093701A patent/PL360937A1/xx not_active Application Discontinuation
-
2002
- 2002-06-13 ZA ZA200204771A patent/ZA200204771B/en unknown
- 2002-06-17 NO NO20022894A patent/NO20022894L/no unknown
-
2003
- 2003-04-14 IS IS6784A patent/IS6784A/is unknown
Also Published As
Publication number | Publication date |
---|---|
SE0003766D0 (sv) | 2000-10-18 |
PL360937A1 (en) | 2004-09-20 |
IL150104A0 (en) | 2002-12-01 |
KR20020062970A (ko) | 2002-07-31 |
ZA200204771B (en) | 2003-09-15 |
MXPA03003417A (es) | 2003-08-07 |
AU2001294002A1 (en) | 2002-04-29 |
WO2002032428A1 (en) | 2002-04-25 |
HUP0301087A2 (hu) | 2003-11-28 |
HUP0301087A3 (en) | 2005-06-28 |
NZ525371A (en) | 2004-11-26 |
SK4732003A3 (en) | 2003-10-07 |
US20050101611A1 (en) | 2005-05-12 |
NO20022894L (no) | 2002-08-15 |
EP1351692A1 (en) | 2003-10-15 |
IS6784A (is) | 2003-04-14 |
CA2425831A1 (en) | 2002-04-25 |
NO20022894D0 (no) | 2002-06-17 |
JP2004511521A (ja) | 2004-04-15 |
CN1400902A (zh) | 2003-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0107333A (pt) | Formulação farmacêutica, uso da mesma, métodos para tratamento profilático ou terapêutico de um indivìduo sofrendo de, ou susceptìvel a, hipercolesterolemia e diarréia, e, uso de um aglutinante de ácidos biliares | |
BR0009835A (pt) | Formulação farmacêutica, uso da mesma, métodos para tratamento profilático ou terapêutico de um indivìduo que sofre, ou susceptìvel à hipercolesterolemia, e a diarréia, e, uso de um aglutinante de ácido da bile | |
TR199901411T2 (xx) | Analjezik etkili yeni bile�imler. | |
TR199901417T2 (xx) | Analjezik etkisi olan yeni bile�imler. | |
BG66114B1 (bg) | Многофазов състав на дросперидон като контрацептив | |
BR9916486A (pt) | Combinações de inibidores do transporte de ácidos biliares no ìleo e inibidores da proteìna de transferência do ester colesteril para indicações cardiovasculares | |
TR200000129T2 (tr) | Yepyeni spiroazabisiklik heterosiklik bileşikler. | |
BR9808013A (pt) | Terapia de combinação empregando benzotiepinas de inibição de transporte de ácido biliar ileal e inibidores de redutase de hmg co-a | |
MXPA03005637A (es) | 1,5- benzotiazepinas y su uso como antihiperlipidemicos. | |
TW362971B (en) | Pharmaceutical composition and kit for treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and a S-phase or M-phase specific anti | |
PT858804E (pt) | Utilizacao de rifaximina como medicamento para o tratamento da diarreia de crisptosporidiose | |
PL343069A1 (en) | Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator | |
CA2433833A1 (en) | Use of flumazenil in developing a drug for the treatment of alcohol dependence | |
TW349865B (en) | Therapeutic agent for hemorrhoidal diseases | |
NZ514558A (en) | Viral treatment | |
EP1626731A4 (en) | ANTI-INFLAMMATORY MEDICINE PREPARATIONS FOR INFLAMMATORY INFLAMMATION AND THE THERAPY OR PROPHYLAXIS OF GASTRIC TOXICITY | |
AU2173101A (en) | Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents | |
IL129267A (en) | Pharmaceutical compositions comprising histamine and/or serotonin for treatment of urinary incontinence | |
JP2002500181A5 (pt) | ||
YU25202A (sh) | Supstituisani piroli kao antiproliferativna sredstva za lečenje kancera | |
DK1462107T3 (da) | Fremgangsmåde til kvindelig kontraception og kit til anvendelse i en sådan fremgangsmåde | |
UA33773C2 (uk) | Засіб для лікування патології нервово-м'язової системи та опірно-рухового апарату "ревмокаїн" | |
AU4918900A (en) | Interferon-beta use in the treatment of ewing's family of tumors | |
AU5890499A (en) | Use of composition in the treatment of schizophrenia | |
MX9707394A (es) | Formulaciones de ridogrel de dosis baja y su uso para el tratamiento de enfermedades intestinales inflamatorias. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 6A., 7A. E 8A. ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2012 DE 28/07/2009. |